Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
16.47
-0.93 (-5.34%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
September 30, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 02, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
July 20, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
July 08, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
June 11, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
May 30, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
April 29, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
April 21, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
March 03, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Upcoming Investor Conferences
February 23, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2026
From
Immunome, Inc.
Via
Business Wire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Pricing of Public Offering of Common Stock
December 16, 2025
From
Immunome, Inc.
Via
Business Wire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Immunome Announces Proposed Public Offering of Common Stock
December 15, 2025
From
Immunome, Inc.
Via
Business Wire
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
December 15, 2025
Via
AB Newswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
